|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial显示文摘 | Edward B Garon Tudor-Eliade Ciuleanu Oscar Arrieta Kumar Prabhash Konstantinos N Syrigos Tuncay Goksel Keunchil Park Vera Gorbunova Ruben Dario Kowalyszyn Joanna Pikiel Grzegorz Czyzewicz Sergey V Orlov Conrad R Lewanski Michael Thomas Paolo Bidoli Shaker | 2014 | The Lancet2014，，： | 2 |
| 2 | Cultural, morphological, pathogenic and molecular variability amongst tomato isolates of Alternaria solani in India显示文摘 | Virendra Kumar Sanchita Haldar Koshlendra K. Pandey Rana P. Singh Achuit K. Singh Prabhash C. Singh | 2008 | World Journal of Microbiology and Biotechnology2008，，7： | 1 |
| 3 | Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxanebased induction chemotherapy and concurrent chemo-radiotherapy in the modern era显示文摘Objective:To evaluate the survival outcomes for a cohort of nasopharyngeal cancer with intracranial extension(ICE)treated with induction chemotherapy(ICT)followed by chemo-intensity-modulated radiotherapy(CTRT)at a tertiary cancer center.Methods:We retrospectively analyzed 45 patients with histologically proven,non-metastatic NPC with ICE treated at our institute between October 2008 and October 2016.Patients were classified as minor ICE or major ICE,based on the extent of ICE.All the patients received 2-3 cycles of a taxane-based ICT regimen followed by CTRT.Radiotherapy was delivered with'riskadapted'intensity-modulated radiotherapy(IMRT)technique in all patients.Results:After a median follow up of 45 months(range:8-113 months),the estimated 5-year DFS,LRFS,DMFS,and OS of the entire cohort was 58%,82%,67%and 74%respectively.On multivariate analysis,histological subtype was an independent predictor of LRFS,and age was an independent predictor of DFS.The extent of ICE showed only a trend towards worse DFS(P=0.06).None of the factors significantly predicted for DMFS or OS.Gender,N-stage,and response to ICT did not significantly affect any of the outcomes.Grade 2 or worse subcutaneous fibrosis was seen in 22%of patients and grade 2 or worse xerostomia was seen in 24%of patients at last follow up.Thirty-three percent of the patients developed clinical hypothyroidism at last follow up.None of the patients experienced any neurological or vascular complications.Conclusions:Taxane-based induction chemotherapy followed by chemo-intensity modulated radiotherapy resulted in excellent locoregional control and survival with acceptable toxicities in patients of nasopharyngeal cancer with intracranial extension.Distant metastasis continues to be the predominant problem in these patients. | Sarbani Ghosh-Laskar Avinash Pilar Carlton Johnny Kumar Prabhash Amit Joshi Jai Prakash Agarwal Tejpal Gupta Ashwini Budrukkar Vedang Murthy Monali Swain Vanita Noronha Vijay Maruthi Patil Prathamesh Pai Deepa Nair Devendra Arvind Chaukar Shivakumar Thiagarajan Gouri Pantvaidya Anuja Deshmukh Pankaj Chaturvedi Sudhir Nair Anil D’Cruz | 2020 | World Journal of Otorhinolaryngology-Head and Neck Surgery2020，6，1： | 1 |
| 4 | Neuroendocrine carcinoma of gallbladder: report of 2 cases显示文摘BACKGROUND: Neuroendocrine carcinoma of the gall- bladder is rare. Its best treatment is not known. METHODS: Two patients underwent surgery earlier: one for suspected cholecystitis and the other for cholelithiasis. Magnetic resonance cholangiopancreatography ( MRCP ) showed residual lesions in the livers. The two patients un- derwent revision surgery followed by chemotherapy. RESULTS; Both patients tolerated the second stage surgery well, which was followed by chemotherapy with paclitaxel, ifosphamide and cisplatin for 6 cycles. They were treated this way for 8 months and 12 months post treatment, re- spectively. CONCLUSIONS: A proper diagnosis of neuroendocrine carcinoma is made often after surgery. As it is a slow grow- ing tumor and not very chemotherapeutically, sensitive sur- gery offers the best local control. | Keechilat Pavithran Kumar Prabhash Diganta Hazarika Dinesh C Doval | 2005 | Hepatobiliary & Pancreatic Diseases International2005，4，1： | 1 |
| 5 | Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study显示文摘 | Giorgio Vittorio Scagliotti Vera Hirsh Salvatore Siena David H. Henry Penella J. Woll Christian Manegold Philippe Solal-Celigny Gladys Rodriguez Maciej Krzakowski Nilesh D. Mehta Lara Lipton José Angel García-Sáenz José Rodrigues Pereira Kumar Prabhash Tu | 2012 | Journal of Thoracic Oncology2012，，12： | 1 |
| 6 | Bone metastases from primary hepatocellular carcinoma simulating multiple myeloma显示文摘A 65-year-old man presented with bone pains and anemia. Skull X-ray revealed multiple osteolytic lesions. The pa- tient was evaluated for multiple myeloma but detailed workup revealed the diagnosis of primary hepatocellular carcinoma (HCC) with osteolytic bone metastases. Thus, bone metastases due to HCC, although rare, should be considered in patients presenting with bone pains due to os- teolytic lesions. | Dinesh Chandra Doval Komal Bhatia Ashok Kumar Vaid Kumar Prabhash Amarnath Jena Digant Hazarika | 2005 | Hepatobiliary & Pancreatic Diseases International2005，4，2： | 0 |
| 7 | First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen(IPSOS):a phase 3,global,multicentre,open-label,randomised controlled study显示文摘Background:Despite immunotherapy advancements for patients with advanced or metastatic non-small-cell lung cancer(NSCLC),pivotal first-line trials were limited to patients with an Eastern Cooperative Oncology Group performance status(ECOG PS)0-1 and a median age of 65 years or younger.We aimed to compare the efficacy and safety of first-line atezolizumab monotherapy with single-agent chemotherapy in patients ineligible for platinum-based chemotherapy.Methods:This trial was a phase 3,open-label,randomised controlled study conducted at 91 sites in 23 countries across Asia,Europe,North America,and South America.Eligible patients had stage IIIB or IV NSCLC in whom platinum-doublet chemotherapy was deemed unsuitable by the investigator due to an ECOG PS 2 or 3,or alternatively,being 70 years or older with an ECOG PS 0-1 with substantial comorbidities or contraindications for platinum-doublet chemotherapy.Patients were randomised 2:1 by permuted-block randomisation(block size of six)to receive 1200 mg of atezolizumab given intravenously every 3 weeks or single-agent chemotherapy(vinorelbine[oral or intravenous]or gemcitabine[intravenous];dosing per local label)at 3-weekly or 4-weekly cycles.The primary endpoint was overall survival assessed in the intention-to-treat population.Safety analyses were conducted in the safety-evaluable population,which included all randomised patients who received any amount of atezolizumab or chemotherapy.This trial is registered with ClinicalTrials.gov,NCT03191786. | Siow Ming Lee Christian Schulz Kumar Prabhash | 2023 | 四川生理科学杂志2023，45，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员